Genetic and Epigenetic Tumor Suppressor Gene Silencing Are Distinct Molecular Phenotypes Driven by Growth Promoting Mutations in Nonsmall Cell Lung Cancer

Table 1

Demographics of the NSCLC case series.

Characteristic
Age, mean (SD)	66.9(10.6)
Gender, n (prevalence)
Female	80(0.45)
Male	97(0.55)
Histology, n (prevalence)
Adenocarcinoma	95(0.54)
Adeno-squamous	5(0.03)
Bronchoalveolar	2(0.01)
Large cell	14(0.08)
Squamous cell	61(0.34)
Tumor TNM stage, n (prevalence)
Stage 1	99(0.56)
Stage 2	34(0.19)
Stage 3	39(0.22)
Stage 4	5(0.03)
Smoking status, n (prevalence)
Never	13(0.07)
Former	93(0.52)
Current	71(0.40)
KRAS codon 12 mutation, n (prevalence)
No	147(0.83)
Yes	30(0.17)
3p21 LOH fraction allelic loss score, n (prevalence)^∗
0–0.3	100(0.66)
>0.3	52(0.34)

^∗3p21 LOH data not available for 25 samples.